Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.64 USD
Change Today -0.09 / -3.30%
Volume 583.3K
BIOC On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for biocept inc (BIOC)

Biocept, Inc. may have more financial risk than other companies in the Biotechnology industry as it is one of the most highly leveraged. Its Debt to Total Capital ratio stands at 104.70%. Biocept, Inc. may have more financial risk than other companies in the Biotechnology industry. It remains one of the most highly leveraged, despite its Debt to Total Capital ratio shrinking to 104.70% over the last fiscal year. However, an examination of near-term assets and liabilities shows that there are enough liquid assets to satisfy current obligations. Accounts Receivable are among the industry's worst with 27.08 days worth of sales outstanding. This implies that revenues are not being collected in an efficient manner. Last, Biocept, Inc. is among the least efficient in its industry at managing inventories, with 23.67 days of its Cost of Goods Sold tied up in Inventories.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Dec 31
2012
Dec 31
2013
Dec 31
2014
4 Year
Trend
Assets    
Cash and Equivalents0.40.20.15.4
TOTAL CASH AND SHORT TERM INVESTMENTS0.40.20.15.4
Accounts Receivable0.00.00.00.0
TOTAL RECEIVABLES0.00.00.00.0
Inventory--0.10.10.2
Prepaid Expenses0.40.30.30.3
Other Current Assets----0.50.1
TOTAL CURRENT ASSETS0.80.61.05.9
Gross Property Plant and Equipment4.74.74.75.3
Accumulated Depreciation-3.7-4.1-4.4-4.6
NET PROPERTY PLANT AND EQUIPMENT1.00.60.40.7
Other Long-Term Assets0.30.30.00.0
TOTAL ASSETS2.11.51.36.6
    
LIABILITIES & EQUITY    
Accounts Payable1.01.41.50.6
Accrued Expenses1.23.32.20.7
Short-Term Borrowings----2.0--
Current Portion of Long-Term Debt/Capital Lease12.421.95.40.1
Other Current Liabilities, Total0.91.02.10.0
TOTAL CURRENT LIABILITIES15.527.613.31.4
Long-Term Debt1.70.7--4.8
Other Non-Current Liabilities0.30.50.50.6
TOTAL LIABILITIES17.428.913.86.8
Preferred Stock Convertible0.00.00.0--
TOTAL PREFERRED EQUITY0.00.00.0--
Common Stock0.00.00.00.0
Additional Paid in Capital85.585.8110.0138.1
Retained Earnings-100.9-113.2-122.4-138.3
TOTAL COMMON EQUITY-15.4-27.4-12.5-0.2
TOTAL EQUITY-15.4-27.4-12.5-0.2
TOTAL LIABILITIES AND EQUITY2.11.51.36.6
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $2.64 USD -0.09

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.15 USD -0.03
BioMerieux €96.11 EUR -0.16
Fluidigm Corp $22.93 USD -0.50
Illumina Inc $220.07 USD -0.61
Laboratory Corp of America Holdings $120.75 USD -1.44
View Industry Companies
 

Industry Analysis

BIOC

Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 111.0x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 96.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.